MIRM / Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals has two drugs, maralixibat and volixibat, targeting rare liver diseases involving cholestasis. The company's lead program, maral more_horizontal

Mirum Pharmaceuticals, Inc. (MIRM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions more_horizontal

Mirum Pharma (MIRM) surges 42% year to date due to encouraging progress in label-expansion efforts of Livmarli, along with strategic initiatives, to e more_horizontal

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Andrew McKibben – Vice Pr more_horizontal

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.81. This comp more_horizontal

Results from the phase 2b EMBARK study, which is using LIMVARLI for the treatment of patients with biliary atresia, are expected in the 2nd half of 20 more_horizontal

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q1 2023 Earnings Conference Call May 6, 2023 4:30 PM ET Company Participants Andrew McKibben - Vice Preside more_horizontal

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.96. This comp more_horizontal